(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.

UNLABELLED: The cytotoxicity and tumor-targeting properties of the anti-HER2/neu monoclonal antibody trastuzumab modified with peptides (CGYGPKKKRKVGG) harboring the nuclear localization sequence ([NLS] italicized) of simian virus 40 large T-antigen and radiolabeled with (111)In were evaluated. METH...

Full description

Bibliographic Details
Main Authors:	Costantini, D, Chan, C, Cai, Z, Vallis, K, Reilly, R
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
by: Costantini, D, et al.
Published: (2010)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
by: Costantini, D, et al.
Published: (2008)

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
by: Cornelissen, B, et al.
Published: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
by: McLarty, K, et al.
Published: (2009)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
by: Reilly, R, et al.
Published: (2006)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
by: Costantini, D, et al.
Published: (2010)

In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
by: Cornelissen, B, et al.
Published: (2009)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
by: Reilly, R, et al.
Published: (2004)

Herceptin resistance in HER2-moderately expressed breast cancer
by: Kerry, J, et al.
Published: (2012)

Auger electron therapy using In-111-labelled F3 peptide
by: Cornelissen, B, et al.
Published: (2011)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
by: Bailey, K, et al.
Published: (2007)

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
by: Cornelissen, B, et al.
Published: (2008)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
by: Gijsen, M, et al.
Published: (2010)

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
by: McLarty, K, et al.
Published: (2009)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer
by: Gijsen, M, et al.
Published: (2010)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
by: Chen, P, et al.
Published: (2001)

Single cell S-value calculations of a stochastic cascade model for Auger-electron emitting radionuclides
by: Vallis, K, et al.
Published: (2016)

Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells
by: Kersemans, V, et al.
Published: (2006)

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
by: Arshad, M, et al.
Published: (2024)

Internalization of Auger electron-emitting isotopes into cancer cells: A method for spatial distribution determination of equivalent source terms
by: Vallis, K, et al.
Published: (2016)

Beam dynamics for the NLS superconducting LINAC
by: Bartolini, R, et al.
Published: (2010)

X-ray reverberation in NLS1
by: Miller, L, et al.
Published: (2011)

On origin and dynamics of the discrete NLS equation /
by: 407613 Hadzievski, Ljupco, et al.
Published: (2000)

Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
by: Wang, J, et al.
Published: (2001)

Absorbed dose evaluation of auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values
by: Falzone, N, et al.
Published: (2017)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
by: Iwata, Hiroji, et al.
Published: (2019)

On the high–low method for NLS on the hyperbolic space
by: Staffilani, Gigliola, et al.
Published: (2021)

On long time dynamic and singularity formation of NLS
by: Fan, Chenjie.
Published: (2017)

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
by: Reilly, R, et al.
Published: (2000)

The identification and validation of Auger electron-emitting radiopharmaceuticals targeting telomerase for cancer therapy
by: Jackson, M
Published: (2013)

Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
by: Cornelissen, B, et al.
Published: (2007)

Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.
by: Falzone, N, et al.
Published: (2012)

Targeting the nucleus: an overview of Auger-electron radionuclide therapy.
by: Cornelissen, B, et al.
Published: (2010)

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
by: Early Breast Cancer Trialists’ Collaborative group (EBCTCG)
Published: (2021)

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
by: Reilly, R, et al.
Published: (2000)

In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR
by: Reilly, R, et al.
Published: (2000)

Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis
by: Winters, Z, et al.
Published: (2003)